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Background: Lymphomatoid papulosis (LyP) is a rare condition within the spectrum of CD30þ cutaneous
lymphoproliferative disorders that is not well documented in Taiwan. This study aimed to analyze its
clinical manifestations, diagnostic histopathology, clinical course, and treatment response among
Taiwanese.
Methods: A retrospective chart review was performed on patients diagnosed with LyP at a Taiwanese
medical center from 1992 to 2008.
Results: There were 34 patients with biopsy-proven LyP. The mean age at diagnosis was 36 years (range:
10e75 years), with male predominance (male:female ratio 3:2). Type-A LyP was identiﬁed in 32 patients
and Type C in 2 patients. Seven cases showed CD4 predominance and six cases showed CD8 predomi-
nance. Of the 34 LyP patients, 2 had coexistent non-Hodgkin’s lymphoma, 1 (3%, 1/34) diagnosed before
LyP onset and 1 (3%, 1/34) developed lymphoma 3 years after LyP. All of the patients were alive after
a mean of 5.2 years (range: 3e12.7 years) of follow-up.
Conclusions: Most of our cases are Type A LyP. No clinical features or pathologic features can predict
increased risk for developing malignancy. Although only 6% (2/34) of LyP patients were found to have
lymphoma in 3-year follow-up, longer follow up is needed. Regardless of treatment modalities, two-
thirds of the patients have a recurrent and relapsing course. Observation is a reasonable approach for
patients without cosmetic or symptomatic concerns.
Copyright  2011, Taiwanese Dermatological Association. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Lymphomatoid papulosis (LyP) is a rare skin disease within the
spectrum of CD30þ cutaneous lymphoproliferative disorders. This
self-healing, paradoxical, rhythmic eruption is histologically malig-
nant but clinically benign.1e3 The recurrent crops of ulcerating,
necrotic papulonodules usually regress spontaneously, leaving
residual scars or areas of altered pigmentation. The life cycle of
a papule is usually 4e8 weeks, whereas nodules may take several
months to resolve.1e3
The most common histopathologic subtype of adult-onset LyP is
Type A, which is characterized by large, atypical, CD30þlogy, Chang Gung Memorial
an.
Hui).
iwanese Dermatological Associatiolymphocytes, resembling Reed-Sternberg cells from Hodgkin’s
lymphoma, and presented in a wedge-shaped distribution
throughout the dermis and mixed with various numbers of
inﬂammatory cells. Type B is less common and characterized by
small, CD30 lymphocytic cells with cerebriform nuclei in a band-
like pattern, with concomitant epidermotropism. Type C is rarer
and consists of a monotonous population of large, atypical, CD30þ
cells diffusely inﬁltrating the dermis, with fewer associated
inﬂammatory cells than those seen in the other types.4,5
LyP patients have increased risk of developing lymphoid
malignancies, including mycosis fungoides, Hodgkin’s disease, and
cutaneous and systemic CD30þ large-cell lymphoma.6 Reported
case series have estimated the risk of lymphoma varied from 10% to
80% after 15-year follow-up.5e7 Despite several case series for LyP
have been carried out in recent years, there has been no Asian
series reported in English-language literature. This study aimed ton. Published by Elsevier Taiwan LLC. All rights reserved.
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ical course, and treatment response among Taiwanese.Patients and methods
We reviewed 34 cases of LyP diagnosed at a medical center in Taipei
from 1992 to 2008. In all patients, general physical examinations
and routine hematologic exams were performed. Clinical presen-
tation and pathologic ﬁndings, including immunohistochemical
stainings for CD2, CD3, CD4, CD8, CD20, CD30, T-cell intracellular
antigen-1 (TIA-1), and anaplastic lymphoma kinase (ALK) were
reviewed. Follow-up data were obtained through chart review or
phone contact with patients.Results
Clinical features
Of the 34 LyP patients, there were 23 men and 11 women. The
mean age at onset of LyP skin lesion was 36 with a range from 10
years to 75 years. The mean disease duration was 4.3 years (1
monthe9.6 years), whereas the follow-up was 5.2 years (3
yearse12.7 years). Most patients (70.6%, 24/34) developed
generalized lesions on limbs and trunk (Figures 1A and 1B),
whereas six showed localized LyP. Two patients had papules on
the limbs only, whereas one had them only on the upper limbs.
One patient had red papules and vesicles on the neck, whereas
another had an indurated ulcer on the left thigh. The average
number of lesions varied greatly, from several to more than 50.
Twenty patients suffered from pruritus associated with the
lesions. None of the patients had systemic involvement at diag-
nosis. The results were summarized in Table 1.Figure 1 (A) Clinical pictures of Patient 15ddiscrete erythematous to violaceous pap
20derythematous and violaceous papules with evidence of central necrosis involving t
erythematous nodules 2e8 mm in size, some with hemorrhagic crusts on right lower limb. (
left forearm.Histology
Cases were divided according to histopathologic ﬁndings, namely
LyP Type A, B, or C (Table 1). Most cases (94%, 32/34) showed
ﬁndings of LyP Type A with dermal inﬁltrates of CD30þ large
atypical cells with convoluted nuclei, mixedwith neutrophils, small
lymphocytes, and occasional eosinophils (Figure 2). Six of the 21
patients had CD8-predominant LyP and 7 patients had CD4-
predominant LyP, although immunoperoxidase staining was not
performed with antileukocyte monoclonal antibodies against CD4
and CD8 in 11 patients. Six were negative for both CD4 and CD8,
and twowere positive for both CD4 and CD8. No notable differences
distinguished CD8-predominant from CD4-predominant LyP.
None of the biopsy specimens had features compatible with
Type B LyP. But two samples (n¼ 2, 6%) revealed patchy dermal
inﬁltrates of large CD30þ anaplastic lymphocytes with epidermo-
tropism, hemorrhage, and few inﬂammatory cells. These two
patients were classiﬁed as Type C LyP (diffuse large cell type).
Laboratory investigation
Routine laboratory examinations were within normal limits for all
patients. Testing for speciﬁc antibodies against human T-cell
leukemia virus-1 antigens in ﬁve patients showed negative results.
Clinical course and treatment
Most patients (94%, 32/34) did not have other malignancy or
lymphoma signs. Four patients had childhood-onset LyP, but none
developed non-Hodgkin’s lymphoma after follow-up for 3 years.
One patient (3%, 1/34, Patient 17) had pre-existing lymphoma
diagnosed 2 years before the onset of LyP and another (3%, 1/34,
Patient 28) developed lymphoma afterwards. For the latter, theules and hemorrhaging center on the abdomen. (B) Clinical pictures of Patient
he left forearm similar to pityriasis lichenoides et varioliformis acuta. (C) Purpuric,
D) Clinical pictures of Patient 16dmultiple erythematous dermal papulonodules on the
Table 1 Clinical and pathologic features of lymphomatoid papulosis in patients who underwent therapy and follow-up.
Patient no./sex/age
of diagnosis
Type of LyP lesions Distribution
of LyP lesions





1/F/51 Papules/nodules Extremities A/NA 3 yr 72 RA, UVA, TS/OBS Off and on
2/M/73 Papules/nodules Extremities A/NA 6 mo 60 RA, TS Subsided
3/F/34 Papules/nodules Extremities A/NA 6 mo 80 RA Subsided
4/F/61 Papules/nodules Extremities A/NA 2 mo NA UVB Subsided
5/M/72 Papules/nodules Generalized C/NA 1 mo 72 RA, UVB NA
6/M/52 Papules/nodules Generalized A/NA 2 mo 42 RA/OBS Off and on
7/F/42 Papules/nodules Generalized C/NA 5þ yr 66 RA/OBS Off and on
8/M/42 Papules/nodules Legs A/NA 1 mo 36 Dapsone Subsided
9/M/12 Papules/nodules Generalized A/CD8 2 wk 38 TS Subsided
10/F/59 Papules/nodules Generalized A/NA 1 mo 72 RA/OBS Off and on
11/M/28 Plaques Extremities A/NA 2 mo 40 Dapsone Subsided
12/M/46 Plaques/ulcers Left leg (localized) A/NA 2 mo 172 RT/OBS Subsided
13/F/58 Papules/nodules Extremities A/CD4 3þ mo 36 CT/RA/OBS Off and on
14/F/22 Papules/nodules Generalized A/NA 1.5 mo 36 OS, RA Subsided
15/M/38 Papules/nodules Generalized A/NA 1 mo 60 RA, UVB, Ab Subsided
16/F/29 Papules/nodules Generalized A/null cell 2 mo 37 AH, TS Subsided
17/M/20* Plaques Generalized A/CD4 2 mo 36 CT/OBS Off and on
18/M/36 Papules/nodules Scalp (localized) A/CD8 9þ yr 38 AH, TS Subsided
19/F/19 Papules/nodules Extremities A/CD4 1 mo 38 OS/OBS Off and on
20/F/15 Papules/nodules Generalized A/CD8 2 mo 72 Ab/OBS Off and on
21/M/74 Papules/nodules Generalized A/null cell 1 mo 60 MTX/OBS Off and on
22/M/32 Papules/nodules Generalized A/CD8 2 mo 72 Ab/OBS Off and on
23/M/69 Papules/nodules Generalized A/null cell 2 mo 48 Ab/OBS Off and on
24/M/40 Vesicles/bullae Right hand (localized) A/CD8 1 mo 48 Ab/OBS Off and on
25/M/62 Papules/nodules Neck (localized) A/null cell 1 yr 48 SE/OBS Off and on
26/M/44 Papules/nodules Right breast (localized) A/CD8 2 mo 60 AH, TS/OBS Off and on
27/M/45 Papules/nodules Generalized A/CD4 CD8 1 mo 97 AH, TS/OBS Off and on
28/M/41y Papules/nodules Generalized A/CD4 2 mo 84 PUVA, RA/OBS Off and on
29/F/56 Papules/nodules Right breast (localized) A/CD4 1 mo 96 TS/OBS Off and on
30/M/41 Papules/nodules Generalized A/CD4 1.5 mo 60 OS/OBS Off and on
31/F/75 Papules/nodules Left leg A/CD4 2 mo 72 TS/OBS Off and on
32/M/50 Papules/nodules Generalized A/CD4 CD8 2 mo 84 TSþMTX/OBS Off and on
33/M/15 Papules/nodules Generalized A/null cell 1 yr 96 MTX, OS, TS/OBS Off and on
34/M/10 Papules/nodules Generalized A/null cell 2 mo 96 OS, TS/OBS Off and on
* Anaplastic large cell lymphoma, Ann Arbor Stage IVA s/p autologous stem cell transplantation and chemotherapy;
y Anaplastic large cell lymphoma developed during follow-up.
Ab¼ antibiotic; AH¼ antihistamines; CT¼ chemotherapy; LyP¼ lymphomatoid papulosis; MTX¼methotrexate; NA¼ not applicable; OBS¼ observation; OS¼ oral cortico-
steroid; PUVA¼ psoralen UV-A; RA¼ retinoid acid; RT¼ radiation therapy; SE¼ surgical excision; TS¼ topical corticosteroid.
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lymphoma (anaplastic large T-cell lymphoma [ALCL]). Patient 28
was treated with oral isotretinoin and phototherapy, whereas
Patient 17 had received autologous stem cell transplantation before
onset of LyP and was undergoing chemotherapy. Both cases had
recurrent eruption of LyP despite treatment. One-third of these 34
patients resolved in a mean 2.8 years and two-thirds of these 34
patients had a recurrent and relapsing course.
Eleven patients (Patients 1e3, 5e7, 10, 13e15, and 28) were
treated with oral 13-cis retinoid acid (RA) (20e30 mg/d). Ten had
dramatic improvement in lesions after 3e4 months of treatment,
except for Patient 1, who stopped 13-cis RA because of intolerable
side effects. Four patients achieved complete remission; Patients 2,
3, and 7 in 3 months and Patient 14 in 4 months. After dis-
continuing therapy, two patients (Patients 3 and 7) experienced
relapses but remitted after treatment. Patient 13 was ﬁrst treated
with cyclophosphamide, hydroxydaunorubicin, vincristine, and
prednisone (CHOP) chemotherapy at another hospital with quick
response to each course of CHOP but relapsed later. After three
courses, the regimen was shifted to 13-cis RA (1 mg/kg/d) and
interferon-a (3 MU/d for 5 days/wk) for 1 year. Her lesions still
waxed and waned after treatment.
Patient 12 presented with indurated ulcers on left thigh and was
initially diagnosed with immunoblastic lymphoma. He was then
treated with radiotherapy with complete remission. However, two
satellite lesions were observed 1 year later and a second skin biopsy
revealed LyP Type A. The papules spontaneously resolved in 2 years.
Other treatment modalities used in combination included pho-
totherapy (ﬁve patients), Dapsone (two patients), oral antihistamineand topical steroids (nine patients), oral doxycycline (two patients),
chemotherapy (one patient), oral methotrexate (three patients), and
surgical excision (one patient).
Neither clinical appearance nor the maximum number of LyP
lesions correlated signiﬁcantly with remission rate, disease activity,
or malignant transformation.
Discussion
The clinical characteristics of our LyP patients are similar to those in
prior studies (Table 2).5,8e12 But patients with LyP in this series have
lower associated hematolymphoid malignancy (6%, 2/34) than in
previous reports. A smaller cohort and inadequate follow-up period
(3e12.7 years) may explain the discrepancy. Since lymphoma can
be found up to 41 years after LyP,13 whether LyP in Asian ethnic
groups have a more benign course needs longer follow-up data.
There is no difference in the clinical picture and histology of LyP
between patients who developed malignant lymphoma and those
who did not. Consistent with previous reports, most of our cases are
Type A LyP.We noted a higher incidence of CD8-predominant cases,
the signiﬁcance of which remains to be elucidated.14 There are no
clinical or pathologic features distinguishing CD4-predominant
from CD8-predominant cases. A CD8þ phenotype in lymphoproli-
ferative disorders is commonly associated with cytotoxic features
and may be associated with aggressive lymphoma,14 but we do not
observe a poorer prognosis in this group of patients. In this study,
the overall survival of LyP patients is excellent. Prior studies have
also shown excellent overall survival of 62%e89% (Table 2).5,8e12
The development of primary cutaneous ALCL for patients with
Figure 2 (A) Dermal inﬁltration by large atypical lymphocytes (H&E; original magni-
ﬁcation: 100). (B) Large atypical lymphocytes have convoluted nuclei mixed with
neutrophils, small lymphocytes, and occasional eosinophils and mitotic ﬁgures (H&E;
original magniﬁcation, 400). (C) Immunohistochemistry shows multiple, large
atypical cells that are CD30þ large atypical lymphocytes (original magniﬁcation,
400). H&E¼ hematoxylin and eosin stain.
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primary cutaneous ALCL that develops de novo.15
LyP is a rare dermatosis in children. Three distinct clinical
presentations have been described. The ﬁrst type involves small
outbreaks after initial eruption resolved.16 The second type has LyP
localized in one area for years before becoming generalized,
whereas the third type involves hundreds of lesions.17 In our series,
four patients had onset before 18 years of agewith clinical course astheﬁrst type. No lymphomawas found in 3-year follow-up (Table 1).
Tamar et al17 have also shown that LyP in children does not differ
from LyP in adults, including risk of lymphoid malignancies.
The most controversial aspect of LyP is its pathogenesis and
classiﬁcation as a benign or malignant disease.18 Neoplastic path-
ogenesis is supported by the higher incidence of lymphomas in LyP
and pathological ﬁndings of the malignant large atypical cells
indistinguishable from transformed mycosis fungoides or ALCL.
Reactive etiology is supported by the presence of LyP development
a few weeks after bacterial, viral, or yeast infection and resolved
after antimicrobial treatment.19 Most patients with LyP remain in
good health, but lymphoid malignancies occur in 8.6%e26.3%.5,8e12
Cutaneous CD30þ ALCL; mycosis fungoides; systemic malignant
lymphomas, such as Hodgkin’s disease, lymphocytic lymphoma, or
ALCL, have all been documented.20 Cabanillas et al7 note that the
cumulative risk of transformation from LyP to lymphoma is 80%.
The optimal treatment for LyP has yet to be established and
there is no evidence in the literature that the natural course or
malignant transformation can be altered by treatment.21 Thus,
many patients may not require active therapy. Indications for
treatment include cosmetic concerns or symptom relief. We have
no conclusions concerning treatment response because of the
limited number of patients receiving therapy. The high percentage
of partial response can be related to the natural history of LyP, with
spontaneous regression and relapses. Systemic agents or skin-
directed treatments may be warranted in generalized disease.
Therapies shown to be effective in treating LyP include topical
corticosteroids, topical mechlorethamine, oral antibiotics, photo-
therapy, low-dose methotrexate, interferon-a, and bexarotene,13
a retinoid not available in Taiwan. Low-dose oral methotrexate
(5e20 mg/wk) is the most effective therapy to suppress the
development of new skin lesions.21 In this series, three patients
were treated withmethotrexate. However, after discontinuation of
treatment, the disease relapsed within months. The 13-cis deriv-
ative of RA, isotretinoin, has been shown to produce good response
for refractory Ki-1þ (CD30) ALCL. Cellular differentiation and
apoptosis were found in the remitting tumors.22,23 In this study, 11
patients were treated with isotretinoin (20e30 mg/d) and 10
patients achieved remission after 3e4 months of medication. This
supports the effectiveness of isotretinoin.20 However, the 66%
relapse rate in our series suggests that no treatment can modify
the disease course. Overly aggressive and potentially harmful
chemotherapy may adversely affect the body’s tumor surveillance
system, allowing progression of ongoing LyP. Observation and
a less toxic therapy may be all that is required as long as systemic
evaluations are negative.
Although there is consensus that all patients with LyP require
long-term observation concerning lymphoma development, there
are few established guidelines.24 A lymphoma-complicating LyP
can be recognized by enlarging or persistent skin lesions, periph-
eral lymphadenopathy, or circulating atypical lymphocytes.
Therefore, annual physical examination with biopsy of suspected
skin lesions or enlarged lymph nodes for histologic, immunopath-
ologic, and cytogenetic or gene rearrangement studies have been
suggested for follow-up.25,26
Our study provides data on the association between Lyp and
other lymphoproliferative disorders, as well as on the prognosis of
LyP patients in Taiwan. This study is limited by the small sample
size and retrospective design. Associated studies, including
peripheral blood T-cell ﬂow cytometry, T-cell receptor gene rear-
rangement, and recording any history of acute viral infections (i.e.
herpes simplex, herpes varicella zoster, and mononucleosis), as
well as serology testing for cytomegalovirus, Epstein-Barr virus,
and herpes simplex virus are lacking.19 As such, further analysis of
possible risk factors and prognostic factors cannot be done.
Table 2 Comparison of clinical features and follow-up in different series of lymphomatoid papulosis.
Our study Sanchez et al5 Christensen et al8 El-Azhary et al9 Tomaszewski et al10 Wang et al11 Bekkenk et al12
Patient no. 34 31 41 53 50 57 118
Sex (male/female) 23/11 20/11 19/22 37/16 37/13 28/29 69/49
Age of onset, yr (range, mean) 10e75, 36 11e68, 35 20e75, 42.7 11e9, 40 2e74, 44 7e81, 45 4e88, 45.5
Duration of LyP (range, mean) 1 moe9.6 yr, 4.3 yr 3 moe38 yr,
9 yr
1e37 yr, 16 yr 6 moe40 yr, 11.9 yr 2 moe33 yr,
15 yr
1e35 yr, 9.2 yr 8 moe29 yr,
12.4 yr




1e44 yr, 12.2 yr 1.5e22.4 yr,
6.5 yr
1e26.6 yr, 5.7 yr 1e29.2 yr,
6.4 yr
Clinical lesions
Papules/nodules 30 31 29 46 50 48 110
Plaques 3 0 5 N/A 0 6 8
Vesicles, bullae 1 0 7 N/A 0 3 0
Associated with lymphoma 2/34 (6%) 6/31 (19%) 6/41 (15%) 8/53 (15%) 3/35 (9%) 15/57 (26%) 23/118 (18%)
Current status (patients) 33* N/A N/A 42 35 57 118
No evidence of disease 10 (30%) N/A N/A 3 (7%) 2 (6%) N/A 38 (32%)
Alive with disease 33 (100%) N/A N/A 35 (83%) 31 (89%) N/A 73 (62%)
Died of lymphoma 0 N/A N/A 4 (10%) 0 1 (2%) 2 (2%)
Died of other causes 0 N/A N/A 0 2 (6%) 3 (5%) 5 (4%)
* One patient was lost to follow-up.
LyP¼ ymphomatoid papulosis; N/A¼ not applicable.
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Despite inherent limitations of a retrospective design and signiﬁ-
cant referral bias stemming from a single institution, this descrip-
tive series provides information on LyP in Taiwan. No clinical
features or pathologic features can predict increased risk for
developing malignancy. Although only 6% (2/34) of LyP patients
were found to have lymphoma in 3-year follow-up, longer follow-
up is needed. Regardless of treatment modalities, two-thirds of the
patients have a recurrent course. Observation is a reasonable
approach for patients without cosmetic or symptomatic concerns.
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